Skip to main content
. 2023 Dec 1;102(48):e35408. doi: 10.1097/MD.0000000000035408

Figure 2.

Figure 2.

Differences in survival rates between high and low ASF1B expression groups. (A–C) Low expression of ASF1B predicts a good prognosis in stomach adenocarcinoma (STAD), including overall survival (OS), progression-free survival (PFS), and first progression (FP). (D) ASF1B was also associated with poor OS from the STAD tissues we collected. ASF1B = anti-silencing function 1B.